Enzolytics Inc. (ENZC)

• 24.5 million [21.6 million–25.5 million] people were accessing antiretroviral therapy (end ofJune 2019).
  37.9 million [32.7 million–44.0 million] people globally were living with HIV (end 2018).
  1.7 million [1.4 million–2.3 million] people became newly infected with HIV (end 2018).
  770 000 [570 000–1.1 million] people died from AIDS-related illnesses (end 2018).
  74.9 million [58.3 million–98.1 million] people have become infected with HIV since the start of the epidemic (end 2018).
  32.0 million [23.6 million–43.8 million] people have died from AIDS-related illnesses since the start of the epidemic (end 2018).

Investments

• At the end of 2018, US$ 19.0 billion (constant 2016 dollars) was available for the AIDS response in low- and middle-income countries, almost 1 billion less than in 2017.
  • Around 56% of the total resources for HIV in low- and middle-income countries in 2018 were from domestic sources.
  
  UNAIDS estimates that US$ 26.2 billion (constant 2016 dollars) will be required for the AIDS response in 2020.

___________________________________________________________________________________


Enzolytics Announces the Signing of a Letter of Intent with Creative Biolabs, Inc.

for Licensing and Commercialization of anti-HTLV-1 Monoclonal Antibodies
https://www.creative-biolabs.com/
Press Release July 20-2021
https://finance.yahoo.com/news/enzolytics-announces-signing-letter-intent-113000339.htm

________________________________________




Enzolytics and Lonza Bioscience Combine Technologies to Fast-track Development and

Production of Anti-HIV and Anti-SARS-CoV-2 Monoclonal Antibodies produced by Enzolytics
https://www.lonza.com/
Press release July 21-2021
https://finance.yahoo.com/news/enzolytics-lonza-bioscience-combine-technologies-113000415.html



_________________________________________


July 22 INTERVIEW
with 
James Hicks, Charles Cotropia and Gurav Chandra


http://www.youtube.com/watch?v=mdljO9VLgj0